Skip to main content
SpringerLink
Log in

Postmenopausal Hormone Use and Endometrial Cancer: Reassessment of the Epidemiological Data

  • Chapter
Women’s Health and Menopause

Part of the book series: Medical Science Symposia Series ((MSSS,volume 17))

  • 322 Accesses

Abstract

Cancer of the uterine corpus is the most common pelvic malignancy in women today. As estimated by the American Cancer Society, it accounted for around 36,000 new cases in the United States in 2000, thus affecting 1 in 38 women in their lifetime. More than 95% of these cancers are endometrial carcinomas. Even among Western industrialized countries, annual incidence rates vary substantially, from 10 per 100,000 in Spain to 25 per 100,000 in the U.S.A. The incidence increases steadily with age before reaching a peak between 70 and 74 years [1]. Incidence rates have declined since the early seventies, parallelling the popularity of unopposed estrogen replacement therapy [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ball HG, Elkadry EA. Endometrial cancer: Current concepts and management. Surg Oncol Clin North Am 1998;7:271–84.

    CAS  Google Scholar 

  2. Ziel HK, Finkle WD, Greenland S. Decline in incidence of endometrial cancer following increase in prescriptions for opposed conjugated estrogens in a prepaid health plan. Gynecol Oncol 1998;68:253–55.

    Article  PubMed  CAS  Google Scholar 

  3. Key TJ. Hormones and cancer in humans. Mutat Res 1995;333:59–67.

    Article  PubMed  CAS  Google Scholar 

  4. Kenemans P, van Unnik GA. Postmenopausal sex hormones and cancer of the endometrium and breast. J Br Meno Soc 2000;6(Suppl.3):4–9.

    Google Scholar 

  5. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000;7:227–42.

    Article  PubMed  CAS  Google Scholar 

  6. Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer 1966;19:489–520.

    Article  PubMed  CAS  Google Scholar 

  7. Gusberg SB, Kardon P. Proliferative endometrial response to theca-granulosa cell tumors. Am J Obstet Gynecol 1971;111:633–43.

    PubMed  CAS  Google Scholar 

  8. MacMahon B. Risk factors for endometrial cancer. Gynecol Oncol 1974;2:122–29.

    Article  PubMed  CAS  Google Scholar 

  9. Jafari K, Javaheri G, Ruiz G. Endometrial adenocarcinoma and the Stein-Leventhal syndrome. Obstet Gynecol 1978;51:97–100.

    PubMed  CAS  Google Scholar 

  10. Pettersson B, Adami HO, Bergstrom R, Johansson ED. Menstruation span a time-limited risk factor for endometrial carcinoma. Acta Obstet Gynecol Scand 1986;65:247–55.

    Article  PubMed  CAS  Google Scholar 

  11. Creasman WT. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Sem Oncol 1997;24:S1.

    CAS  Google Scholar 

  12. Klip H, Burger CW, Kenemans P, van Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control 2000;11:319–44.

    Article  PubMed  CAS  Google Scholar 

  13. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995;346:995–1000.

    Article  PubMed  CAS  Google Scholar 

  14. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038–42.

    Article  PubMed  CAS  Google Scholar 

  15. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation [In Process Citation]. Lancet 1999;354:1586–90.

    Article  PubMed  CAS  Google Scholar 

  16. Acken HS, Jr. Estrogen replacement therapy. Obstet Gynecol 1969;34:46–49.

    PubMed  Google Scholar 

  17. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164–67.

    Article  PubMed  CAS  Google Scholar 

  18. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167–70.

    Article  PubMed  CAS  Google Scholar 

  19. Burger CW, Kenemans P. Postmenopausal hormone replacement therapy and cancer of the female genital tract and breast. Curr Opin Obstet Gynecol 1998; 10:41–45.

    Article  PubMed  CAS  Google Scholar 

  20. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749–56.

    Article  PubMed  CAS  Google Scholar 

  21. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 1980;302:551–54.

    Article  PubMed  CAS  Google Scholar 

  22. Kaufman DW, Shapiro S, Slone D, et al. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med 1980;303:1045–47.

    Article  PubMed  CAS  Google Scholar 

  23. Hulka BS, Chambless LE, Kaufman DG, Fowler WC, Jr., Greenberg BG. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 1982; 247:475–77.

    Article  PubMed  CAS  Google Scholar 

  24. Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA 1983;249:1600–1604.

    Article  Google Scholar 

  25. Rosenblatt KA, Thomas DB. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:870–74.

    Article  PubMed  CAS  Google Scholar 

  26. Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 1989;59:445–47.

    Article  PubMed  CAS  Google Scholar 

  27. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J 1989;298:147–51.

    Article  CAS  Google Scholar 

  28. Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 1990;162:148–54.

    PubMed  CAS  Google Scholar 

  29. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338:274–77.

    Article  PubMed  CAS  Google Scholar 

  30. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993;81: 265–71.

    PubMed  CAS  Google Scholar 

  31. Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20–24.

    Article  PubMed  CAS  Google Scholar 

  32. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer [see comments]. J Natl Cancer Inst 1997;89:1110–16.

    Article  PubMed  CAS  Google Scholar 

  33. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458–61.

    Article  PubMed  CAS  Google Scholar 

  34. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen- progestin replacement. Cancer Causes Control 1999;10:253–60.

    Article  PubMed  CAS  Google Scholar 

  35. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353:1824–28.

    Article  PubMed  CAS  Google Scholar 

  36. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–37.

    Article  PubMed  CAS  Google Scholar 

  37. Parslov M, Lidegaard O, Klintorp S, et al. Risk factors among young women with endometrial cancer: A Danish case- control study. Am J Obstet Gynecol 2000;182:23–29.

    Article  PubMed  CAS  Google Scholar 

  38. Jain MG, Rohan TE, Howe GR. Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol 2000;53:385–91.

    Article  PubMed  Google Scholar 

  39. Hill DA, Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456–61.

    Article  PubMed  CAS  Google Scholar 

  40. Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994–1997. Cancer Causes Control 2001;12:111–15.

    Article  PubMed  CAS  Google Scholar 

  41. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta- analysis. Obstet Gynecol 1995;85:304–13.

    Article  PubMed  CAS  Google Scholar 

  42. Gray LA, Sr., Christopherson WM, Hoover RN. Estrogens and endometrial carcinoma. Obstet Gynecol 1977;49:385–89.

    PubMed  Google Scholar 

  43. Weiss NS, Szekely DR, English DR, Schweid AI. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 1979;242:261–64.

    Article  PubMed  CAS  Google Scholar 

  44. Hulka BS, Kaufman DG, Fowler WC, Jr., Grimson RC, Greenberg BG. Predominance of early endometrial cancers after long-term estrogen use. JAMA 1980;244:2419–22.

    Article  PubMed  CAS  Google Scholar 

  45. Buring JE, Bain CJ, Ehrmann RL. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 1986;124:434–41.

    PubMed  CAS  Google Scholar 

  46. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996;276:1397–403.

    Article  PubMed  CAS  Google Scholar 

  47. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262–67.

    Article  PubMed  CAS  Google Scholar 

  48. Levi F, La Vecchia C, Gulie C, Franceschi S, Negri E. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer 1993;29A:1445–49.

    Article  PubMed  CAS  Google Scholar 

  49. Green PK, Weiss NS, McKnight B, Voigt LF, Beresford SA. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 1996;7:575–80.

    Article  PubMed  CAS  Google Scholar 

  50. Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997;10:963–68.

    PubMed  CAS  Google Scholar 

  51. Sherman ME. Theories of endometrial carcinogenesis: A multidisciplinary approach. Mod.Pathol. 2000;13:295–308.

    Article  PubMed  CAS  Google Scholar 

  52. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15: 10–17.

    Article  PubMed  CAS  Google Scholar 

  53. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–78.

    Article  PubMed  CAS  Google Scholar 

  54. Schairer C, Adami HO, Hoover R, Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 1997;8:59–65.

    Article  PubMed  CAS  Google Scholar 

  55. Lobo RA. The role of progestins in hormone replacement therapy. Am J Obstet Gynecol 1992;166:1997–2004.

    PubMed  CAS  Google Scholar 

  56. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol 1979;133:537–47.

    CAS  Google Scholar 

  57. Gambrell RD, Jr., Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732–38.

    PubMed  Google Scholar 

  58. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599–605.

    Article  PubMed  CAS  Google Scholar 

  59. Moyer DL, de Lignieres B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992–97.

    PubMed  CAS  Google Scholar 

  60. Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981;3:145–56.

    Article  PubMed  CAS  Google Scholar 

  61. Spencer CP, Cooper AJ, Whitehead MI. Management of abnormal bleeding in women receiving hormone replacement therapy. Br Med J 1997;315:37–42.

    Article  CAS  Google Scholar 

  62. Mattsson LA, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982;4:95–102.

    Article  PubMed  CAS  Google Scholar 

  63. Magos AL, Brincat M, Studd JW, Wardle P, Schlesinger P, O’Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985;65:496–99.

    PubMed  CAS  Google Scholar 

  64. Doren M, Schneider HP. The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 1996;41:29–39.

    PubMed  CAS  Google Scholar 

  65. Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription: A population-based study. Am J Obstet Gynecol 2000;182:270–76.

    Article  PubMed  CAS  Google Scholar 

  66. Comerci JT, Jr., Fields AL, Runowicz CD, Goldberg GL. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer. Gynecol Oncol 1997; 64:425–30.

    Article  PubMed  CAS  Google Scholar 

  67. Kenemans P, van Unnik GA, Mijatovic V, van der Mooren MJ. Perspectives in hormone replacement therapy. Maturitas 2001;38(Suppl.l):S41–S48.

    Article  PubMed  CAS  Google Scholar 

  68. Wren BG, Brown L. Compliance with hormonal replacement therapy. Maturitas 1991;13: 17–21.

    Article  PubMed  CAS  Google Scholar 

  69. Boerrigter PJ, van de Weijer PH, Baak JP, Fox H, Haspels AA, Kenemans. Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. Maturitas 1996;24:63–71.

    Article  PubMed  CAS  Google Scholar 

  70. Hirvonen E, Salmi T, Puolakka J, et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 1995;21:39–44.

    Article  PubMed  CAS  Google Scholar 

  71. Ettinger B, Selby J, Citron JT, et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83:693–700.

    PubMed  CAS  Google Scholar 

  72. Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999;32:161–70.

    Article  PubMed  CAS  Google Scholar 

  73. Casper RF. Estrogen with interrupted progestin HRT: A review of experimental and clinical studies. Maturitas 2000;34:97–108.

    Article  PubMed  CAS  Google Scholar 

  74. Rozenberg S. Clinical evidence supporting the rationale for constant oestrogen, intermittent progestogen hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 2001;94:86–91.

    Article  PubMed  CAS  Google Scholar 

  75. Moutsatsou P, Sekeris CE. Estrogen and progesterone receptors in the endometrium. Ann NY Acad Sci 1997;816:99–115.

    Article  PubMed  CAS  Google Scholar 

  76. Corson SL, Richart RM, Caubel P, Lim P. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17beta-estradiol and norgestimate on endometrial histology. Int J Fertil Womens Med 1999;44:279–85.

    PubMed  CAS  Google Scholar 

  77. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326–30.

    PubMed  CAS  Google Scholar 

  78. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189–91.

    Article  PubMed  CAS  Google Scholar 

  79. Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195–200.

    Article  PubMed  CAS  Google Scholar 

  80. Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97: 555–60.

    Article  PubMed  CAS  Google Scholar 

  81. Burger CW, van Leeuwen F, Scheele F, Kenemans P. Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 1999;32:69–76.

    Article  PubMed  CAS  Google Scholar 

  82. Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990;113:95–103.

    PubMed  Google Scholar 

  83. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9–16.

    PubMed  Google Scholar 

  84. Baldereschi M, Di CA, Lepore V, et al. Estrogen-replacement therapy and Alzheimer’s disease in the Italian Longitudinal Study on Aging. Neurology 1998;50:996–1002.

    Article  PubMed  CAS  Google Scholar 

  85. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease: A population-based case-control study. Am J Epidemiol 1994;140:262–67.

    PubMed  CAS  Google Scholar 

  86. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995;87:1067–71.

    Article  PubMed  CAS  Google Scholar 

  87. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidemiological studies. Med J Aust 1995;162:491–93.

    PubMed  CAS  Google Scholar 

  88. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women [see comments]. Ann Intern Med 1992;117:1016–37.

    PubMed  CAS  Google Scholar 

  89. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47–63.

    Article  PubMed  CAS  Google Scholar 

  90. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–13.

    Article  PubMed  CAS  Google Scholar 

  91. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522–29.

    Article  PubMed  CAS  Google Scholar 

  92. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: Arandomized, controlled trial. Arterioscler Tromb Vasc Biol 2001;21:262–68.

    Article  CAS  Google Scholar 

  93. Paganini-Hill A. Hormone replacement therapy and stroke: Risk, protection or no effect? Maturitas 2001;38:243–61.

    Article  PubMed  CAS  Google Scholar 

  94. Kenemans P, van Unnik GA, Taets van Amerongen AHM, Scheele F. Hormone replacement treatment options and the breast. Adv Obstet Gynecol 2000;52:255–65.

    Google Scholar 

Download references

Authors
  1. Gijs A. van Unnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Curt W. Burger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kenemans
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Columbia University, New York, New York, USA

    R. A. Lobo

  2. First Department of Obstetrics and Gynecology, University of Milan, Milan, Italy

    P. G. Crosignani  & F. Bruschi  & 

  3. Department of Pharmacological Sciences, University of Milan, Milan, Italy

    R. Paoletti

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

van Unnik, G.A., Burger, C.W., Kenemans, P. (2002). Postmenopausal Hormone Use and Endometrial Cancer: Reassessment of the Epidemiological Data. In: Lobo, R.A., Crosignani, P.G., Paoletti, R., Bruschi, F. (eds) Women’s Health and Menopause. Medical Science Symposia Series, vol 17. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1061-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1061-1_24

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5375-1

  • Online ISBN: 978-1-4615-1061-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation